Enliven Therapeutics, Inc.

NASDAQ:ELVN

Biotechnology

Healthcare
$44.89 -0.27%

-$0.12 today

Market cap
$3.30B
Beta
0.40
P/E (TTM)
-28.4
EPS (TTM)
-$1.57
52W Low $14.79High $48.53

Volume 0.75M

Average 1.35M

ELVN Total Non-current Assets

All assets not expected to be converted to cash within one year.

Enliven Therapeutics, Inc.NASDAQ: ELVN

Total Non-current Assets · Q3 FY2026 · quarter ended Sep 2026

Total non-current assets falls 69.9% from a year ago

Total non-current assets stood at $2.47M at the end of Q3 FY2026, down 69.9% from a year earlier and down 14.4% from the prior quarter. Over 3 fiscal years it compounded at -38.5% a year.

Context

  • Total non-current assets amounted to 0.3% of total assets at the end of Q3 FY2026, down 1.4 pp from a year earlier.
  • Total non-current assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current assets keeps falling in the next quarterly balance sheet after a -69.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.47M-14.4% QoQ
Last fiscal yearDec 2025
$1.29M-83.1% YoY
Year agoSep 2025
$8.19M-69.9% since
Total Non-current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-69.9%——
1 year-83.1%——
3-year CAGR-38.5%——
5-year CAGR——
10-year CAGR——

Total Non-current Assets history

USD · from the balance sheet

Latest · FY2025
1.29M USD
Year-over-year change
-83.1%
4-year CAGR
-16.5%

Total Non-current Assets vs competitors

How ELVN compares with its peers on the latest reported figures

  • ELVN's Sep 2026 total non-current assets of $2.47M is the 9th highest of the 11 companies compared; the peer median is $40.48M.
  • Its year-over-year change of -69.9% is the 8th highest of 11, against a peer median of -21.7%.
  • Total non-current assets amounts to 0.3% of total assets for ELVN, versus a peer median of 5.5%.
ELVN Competitors Peer median
Total Non-current Assets for ELVN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
INCYIncyte CorporationJun 2026$1.31B -39.9%-4.5%16.6%
EXELExelixis, Inc.Jul 2026$1.24B -17.0%-1.2%49.9%
RVMDRevolution Medicines, Inc.Jun 2026$294.93M +16.5%+22.6%6.8%
ORICORIC Pharmaceuticals, Inc.Mar 2026$146.53M +366.3%+45.4%33.5%
CGEMCullinan Therapeutics, Inc.Mar 2026$41.58M -84.1%-10.7%10.3%
RLAYRelay Therapeutics, Inc.Jun 2026$39.38M -18.7%-18.8%4.1%
NUVBNuvation Bio Inc.Jun 2026$18.07M -24.8%+69.1%2.4%
TYRATyra Biosciences, Inc.Mar 2026$17.43M -7.8%+24.5%4.2%
ELVNEnliven Therapeutics, Inc.Sep 2026$2.47M -69.9%-38.5%0.3%
SNDXSyndax Pharmaceuticals, Inc.Mar 2026$1.49M -98.4%-39.8%0.3%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$595K -98.0%+8.8%0.2%
Peer median (excluding ELVN) $40.48M-21.7%+3.8%5.5%

Competitors are the stored peer set for ELVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents110.02M75.54M100.14M124.12M98.9M
Short-term Investments00153.01M189.32M363.73M
Net Receivables00000
Inventory00000
Other Current Assets02.22M10.05M4.69M12.26M
Total Current Assets110.67M77.75M266.15M318.13M474.88M
Property, Plant & Equipment (Net)954K1.52M1.06M458K417K
Goodwill00000
Intangible Assets00000
Long-term Investments054K000
Tax Assets00000
Other Non-current Assets1.71M3.98M4.65M7.18M873K
Total Non-current Assets2.66M5.55M5.72M7.63M1.29M
Total Assets113.33M83.3M271.87M325.76M476.17M
Account Payables2.52M3.44M532K1.34M2.16M
Short-term Debt00000
Tax Payables00000
Deferred Revenue05.51M000
Other Current Liabilities233K320K10.36M204K4.65M
Total Current Liabilities5.75M9.72M25.89M15.92M16.57M
Long-term Debt00000
Deferred Tax Liabilities0000108K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities714K150.41M67K00
Total Non-current Liabilities714K150.41M67K0108K
Total Liabilities6.47M160.12M25.96M15.92M16.68M
Common Stock1K1K41K49K59K
Retained Earnings(45.2M)(82.86M)(154.45M)(243.47M)(347.17M)
Accumulated OCI0(149.75K)141K55K334K
Other Stockholders Equity00000
Minority Interest00000
Total Equity106.86M(76.83M)245.91M309.85M459.6M
Total Debt159K323K335K0399K
Net Debt(109.87M)(75.21M)(99.81M)(124.12M)(98.5M)

Enliven Therapeutics, Inc.

NASDAQ:ELVN

Intrinsic Alpha fair value

Locked

Current Price

$44.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.